Arctic Bioscience: New company presentation

Arctic Bioscience is pleased to announce that a new company presentation is now available.

Arctic Bioscience, the company developing a novel oral treatment (HRO350) for mild-to-moderate psoriasis, a large global market with significant unmet medical need, is pleased to announce that a new company presentation is now available under the investor relations section on the company website and attached to this release.

Danielle Glenn
CFO

Mobile: +47 909 98 201
Email: danielle@arctic-bioscience.com

Arctic Bioscience is a biotech company developing and commercializing nutraceutical and developing pharmaceutical products based on the unique properties of bioactive marine compounds.

The company is developing a novel oral treatment (HRO350) for mild-to-moderate psoriasis, a large global market with significant unmet medical need. Arctic Bioscience will offer convenient treatment based on a natural raw material (herring roe). The nutraceutical business has proven traction in the premium Omega 3 market with global expansion potential in B2C and B2B channels. To support its ambitious long-term growth strategy, Arctic Bioscience is integrating its value chain and investing in a state-of-the-art manufacturing facility with a proprietary production process to enable large-scale high-quality production.

Based in Ørsta on the West Coast of Norway with access to locally sourced herring roe raw material and led by a team with 30+ years of pharma and marine extracts experience, Arctic Bioscience is on a mission to empower healthy lives.